

**Figure 1**






Figure 3A

	G0							G9						
MarkingOligos	0	8	0	8	12	0	12	0	8	0	8	12	0	12
RNaseH	0	0	E	E	0	H	H	0	0	E	E	0	H	H




Figure 3B

MGM abundance			
Before treatment		After treatment	
B52	G9 94% (62/66)	G9-M/M(E)	45% (9/20)
HSF/L	G9 87.5% (7/8)	G9-M/M/M	9% (2/22)
HSF/H	G9 100% (1/1)	G9-M/M/M	3% (1/27)

Figure 4





Figure 5A



Figure 5B

**Figure 6**





Figure 7

**Figure 8A**




Figure 8B

14-1 ATCGCGATACAAAATTAAGTTGAACGCGAGTTCTCCATCT (SEQ ID NO: 28)
14-2 AAGTAGCTAGGAGTCCTTCTCCCCTCAAAACAGAATGGGG (SEQ ID NO: 29)
9a-1 GGCAAGCTACGCGTCAAATAGCAAGCACACCGAAGACACA (SEQ ID NO: 30)

Figure 8C




Figure 9A




Figure 9B